Resistance to sorafenib in HCC can also be driven by the activation of the Akt/β-catenin pathways [17], whereas the inhibition of the JAK/STAT pathways may overcome such resistance [18]. This evidence concerns the gene AKT1 and hepatocellular carcinoma.